Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 23.6 | 31.3 | 38.0 | 46.7 | 56.6 | 30.3 | 31.6 | 66.0 |
| Operating profit | $m | -272 | -286 | ||||||
| Net profit | $m | -48 | -88 | -23 | -114 | -73 | -359 | -447 | - |
| EPS reported | $ | -36.48 | -64.88 | ||||||
| Operating cashflow per share | $ | 0.35 | -2.54 | ||||||
| Capex per share | $ | 0.01 | 0.06 | ||||||
| FCF per share | $ | 0.33 | -2.60 | ||||||
| Free cash flow | $m | 3.7 | -17.9 | ||||||
| Net debt | $m | 122 | 95 | ||||||
| Book value equity | $m | -208 | -308 | ||||||
| Book value per share | $ | -18.83 | -44.74 | ||||||
| Number of shares | m | 11.03 | 6.89 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.65 | -0.01 | ||||||
| P/S LTM | x | 4.45 | 0.13 | ||||||
| P/FCF LTM | x | 36.55 | -0.22 | ||||||
| EV/EBITDA LTM | x | -0.73 | -0.27 | ||||||
| EV/Sales LTM | x | 8.67 | 3.06 | ||||||
| Earnings Yield LTM | % | -266.49% | -11466.0% | ||||||
| FCF Yield | % | 2.74% | -450.21% | ||||||
| Quality | |||||||||
| ROE | % | 172.65% | 189.81% | ||||||
| ROIC | % | 1031.6% | 162.60% | ||||||
| Operating margin | % | -900.09% | -903.52% | ||||||
| Gross margin | % | 49.68% | 41.49% | ||||||
| FCF/Sales | % | 12.17% | -56.69% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -46.54% | -28.55% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | -80.36% | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | - | - | ||||||
| FCF/Debt | x | 0.03 | -0.19 | ||||||
| Net Debt/EBITDA | x | -0.36 | -0.26 | ||||||
| EBIT/Net interest | x | -23.76 | -17.65 | ||||||
| Net debt/market cap | % | 90.30% | 2386.2% | ||||||
| Net debt/Equity | x | -0.59 | -0.31 | ||||||
| Gross debt/equity | x | -0.64 | -0.31 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free